anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
High-resolution esophageal manometry (HREM) is the current modality used to evaluate esophageal motility. There are 2 types of system: water-perfused system that is cheaper to maintain and a solid-state system that is considered to be more sensitive. According to the data obtained in the study of 400 patients and 75 controls by J Pandolfino et al it was proposed to use a common algorithm of HREM data interpretation and the normative values of the parameters used to interpret the color plots of HREM. This formed the basis for the first version of the currently used HREM reporting algorithm and classification of esophageal motility disorders called Chicago Classification (CC). To date, this classification has been updated several times by the International Working Group based on the recently published data. The Working group stated that the proposed normative values still need to be widely studied for each HREM system and in different populations. Some studies has been published recently on the normative values of HREM in different countries (predominantly in the US, in some European countries, Korea, India and China. But there has been no study on the subject in Russia still.
PURPOSE: To obtain a medicinal composition for inhibiting cartilage degradation, containing a specific 2-phenyl-3-aroylbenzothiophene as active ingredient. CONSTITUTION: This medicinal composition for inhibiting cartilage degradation uses, as active ingredient, a compound of formula I [R<1> and R<3> are each H, CH3 , CO(1-6C alkyl) or CO-Ar (Ar is phenyl); R<2> is pyrrolidino or piperidino] or a pharmaceutically acceptable salt or solvate thereof. The compound of formula I is esp. pref. a compound of formula II or hydrochloride thereof, and obtained by using a benzo[b]thiophene bearing both 6-hydroxyl and 2-(4- hydroxyphenyl) groups as starting material followed by protecting, acylating and then deprotecting the starting material. This composition is administered in the form of tables, elixir or liquid, or intramuscularly, intravenously or percutaneously. This composition is capable of inhibiting cartilage degradation developed chronic rheumatic arthritis, psoriatic arthritis, osteoarthrosis, hypertrophic arthritis, osteoarthritis, etc.
PURPOSE: To obtain a cosmetic composition useful as a cleaning mask and further capable of modifying gloss of the face by compounding polyamide particles which are dispersed in an aqueous gel as an essential cleaning agent and have roughly spherical shapes of specific sizes. CONSTITUTION: This cosmetic composition is obtained by compounding an aqueous gel with polyamide particles which are dispersed in the aqueous gel and have roughly spherical shapes of specific sizes, wherein the particles are contained in an amount of >=12 wt.% (especially, 12-35 wt.%) of the total amount. It is preferable that the particles have densities of 1.0-1.84 g/cm<3> , especially 1.02-1.4 g/cm<3> and sizes of 5-50 μm, especially 10-30 μm. Regarding the gel, the gel contains at least one or more kinds of gelling agents in a water-soluble vehicle, and the gelling agent is preferably selected from a water-soluble polymer and a polymer which can give a colloidal solution in water. As the gelling agent, an acrylic polymer, a methacrylic polymer, a carboxyvinylpolymer, etc., is suitable. The composition can be removed simply by washing and rising.  Further, the composition can exhibit visual effect for reducing the depths of wrinkles.
After cavity preparation, clean and boost enamel cleanser of vista apex will be used to clean enamel and dentin surface by three steps: 1. With the enclosed flow-thru brush tip, apply Clean \& Boost to the surface to be cleansed, ensuring the surface is completely saturated. 2. Using the delivery brush tip, agitate the Clean \& Boost on the surface for 10 seconds. 3. Rinse thoroughly. The RE GEN universal adhesive from vista apex will be applied with micro brush with rubbing action then air agitation. RE GEN Bio active flowable composite form vista apex will be added to the universal adhesive and then cured together for 20 seconds according to the manufacture instructions.
OBJECTIVE: To compare and evaluate early and midterm outcomes of a novel no cross approach with short tip vs. standard tip introducer systems for all distal components to prevent target vessel bridging stent kink or collapse during fenestrated endovascular aortic repair (FEVAR).
METHODS: A retrospective analysis was conducted on all patients who underwent FEVAR at a tertiary referral centre between October 2016 and July 2022. The inclusion criterion was the use of renal artery fenestrations. Patients who had chronic dissections were included. Endpoints were analysed in two groups comprising the no cross group and the standard group, with all cases being consecutive in their respective groups. Cone beam computed tomography was used intra-operatively in all cases, and post-operative computed tomography angiograms and re-interventions were reviewed. Primary endpoints included technical success, intra-operative adjunctive procedures, adverse events related to the fenestration, and re-interventions, while secondary endpoints were secondary interventions and overall mortality rate.
RESULTS: Seventy patients (35 in each group) were enrolled in the study, with 64 (91%) having juxtarenal aneurysms. There were no differences in demographics, cardiovascular risk factors, or aneurysm characteristics between the two groups. The no cross group demonstrated a significantly higher technical success rate (100% in all cases) compared with the standard group (29 cases, 83%; p = .010). Additionally, there were statistically significantly fewer intra-operative adjunctive procedures required in the no cross group (1.5% of fenestrations) compared with the standard group (8.2% of fenestrations) (p = .013). The overall median follow up was 32 months (interquartile range 22, 62 months).
CONCLUSION: Implementation of a novel no cross concept during FEVAR, using a short dilator introducer tip on the distal bifurcated component and iliac extensions, significantly reduced intra-operative fenestration related adverse events and enhanced technical success. Further studies with larger patient populations and longer follow up are needed to confirm these findings.
Different kinship and resistance to cotton leaf curl disease (CLCuD) and heat were found between upland cotton cultivars from China and Pakistan. 175 SNPs and 82 InDels loci related to yield, fiber quality, CLCuD, and heat resistance were identified. Elite alleles found in Pakistani accessions aided local adaptation to climatic condition of two countries. Adaptation of upland cotton (Gossypium hirsutum) beyond its center of origin is expected to be driven by tailoring of the genome and genes to enhance yield and quality in new ecological niches. Here, resequencing of 456 upland cotton accessions revealed two distinct kinships according to the associated country. Fiber quality and lint percentage were consistent across kinships, but resistance to cotton leaf curl disease (CLCuD) and heat was distinctly exhibited by accessions from Pakistan, illustrating highly local adaption. A total of 175 SNP and 82 InDel loci related to yield, fiber quality, CLCuD and heat resistance were identified; among them, only two overlapped between Pakistani and Chinese accessions underscoring the divergent domestication and improvement targets in each country. Loci associated with resistance alleles to leaf curl disease and high temperature were largely found in Pakistani accessions to counter these stresses prevalent in Pakistan. These results revealed that breeding activities led to the accumulation of unique alleles and helped upland cotton become adapted to the respective climatic conditions, which will contribute to elucidating the genetic mechanisms that underlie resilience traits and help develop climate-resilient cotton cultivars for use worldwide.
ARICEPT is supplied as film-coated, round tablets containing 5 mg, 10 mg, or 23 mg of donepezil hydrochloride.

  * The 5 mg tablets are white. The strength, in mg (5), is debossed on one side and ARICEPT is debossed on the other side.  

  * The 10 mg tablets are yellow. The strength, in mg (10), is debossed on one side and ARICEPT is debossed on the other side.  

  * The 23 mg tablets are reddish. The strength, in mg (23), is debossed on one side, and ARICEPT is debossed on the other side. 



ARICEPT ODT is supplied as round tablets containing either 5 mg or 10 mg of donepezil hydrochloride.

  * The 5 mg orally disintegrating tablets are white. The strength, in mg (5), is debossed on one side and ARICEPT is debossed on the other side.  

  * The 10 mg orally disintegrating tablets are yellow. The strength, in mg (10), is debossed on one side and ARICEPT is debossed on the other side.
The present disclosure provides nucleotide conjugates each configured to include a core attached to multiple nucleotide-arms, where the nucleotide-arms are modular and comprise (i) a core attachment moiety, (ii) a spacer, (iii) a linker, and (iv) a nucleotide unit. The nucleotide unit of each nucleotide-arm can bind a polymerase which is complexed with a nucleic acid template and nucleic acid primer. The nucleotide unit can bind the 3' end of the primer at a position that is opposite a complementary nucleotide in the template strand. Under suitable conditions, the nucleotide unit of the nucleotide conjugates binds the primer strand but does not undergo polymerase-catalyzed incorporation. The binding event can be detected, and the specific base of the nucleotide unit can be identified. The nucleotide conjugates described herein are useful for nucleic acid sequencing methods, particularly for massively parallel sequencing methods employed for next gen sequencing platforms.
Total knee arthroplasty (TKA) is currently the most common elective surgery in the US and will increase in frequency nearly five-fold by 2030 to 3.5 million surgeries annually. This surgery is most prevalent among older adults with advanced knee osteoarthritis (OA) and its increase is explained primarily by growth in this population. Although TKA reliably reduces joint pain, it fails to correct objectively-measured functional disability due, in part, to dramatic declines in lower-extremity neuromuscular function during the early, postsurgical period. These deficits are never fully remediated, remaining for years after surgery and contributing to persistent disability. Despite these detrimental effects of TKA, the fundamental skeletal muscle adaptations that occur in the early, post-surgical period are poorly defined and understudied and there is currently no widely-accepted, evidence-based intervention to counter these changes. To address this clinical problem, the investigators goals in this application are to define the skeletal muscle structural and functional adaptations following TKA at the whole body, tissue, cellular, organellar and molecular levels in humans in an effort to identify factors contributing to functional disability and to assess the utility of neuromuscular electrical stimulation (NMES) to counter post-surgical muscle adaptations at these same anatomic levels. We hypothesize that TKA fails to remediate physical disability in patients, in part, because of the profound skeletal muscle myofilament and mitochondrial loss and dysfunction that develops during the early, post-surgical period. Moreover, the investigators posit that NMES will improve functional recovery following TKA by countering these early skeletal muscle adaptations. To test this model, the investigators will evaluate participants with knee OA prior to and following TKA for skeletal muscle structure and function at multiple anatomic levels, with patients randomized to receive NMES or sham control intervention during the first 5 weeks post-surgery.
INTRODUCTION: Exomphalos anomaly is defined as the herniation of abdominal viscera into the base of the umbilical cord, with only a membranous sac covering these contents. It has an incidence of approximately 1 in 4000-6000 births. Management of exomphalos major (EM) remains controversial and limited, with very few studies to guide decision-making.
METHOD: This is a case series of four neonates with EM treated at a tertiary paediatric referral centre between 2018 and 2021 with a gradual compression dressing technique.
RESULTS: Four neonates were diagnosed with EM. The average gestational age was 38 + 5 (range 38 + 2 - 39 + 2), and the average birth weight was 3.1 kg (range 2.56 - 3.49 kg). The defect size ranged between 5 and 7 cm. All patients were commenced on gradual compression dressing between days 1 and 3 of life. Dressings were applied at the bedside in the general neonatal ward. The average time taken to reach full feeds was 1 week; only one patient required parenteral nutrition. Three underwent surgical repair at two and 16 weeks of age; one had delayed repair at the age of 1 year because of the COVID-19 pandemic. None required patch repair. None required prolonged ventilation after repair.
CONCLUSION: This case series describes a successful compression dressing technique that reduces sac content without the need for general anaesthetic or respiratory compromise, whereby simultaneous enteral feeding is tolerated.
The present invention relates generally to the field of computer-based image recognition. More particularly, the invention relates to methods and systems for the identification, and optionally the quantitation of, discrete objects of biological origin such as cells, cytoplasmic structures, parasites, parasite ova, and the like which are typically the subject of microscopic analysis. The invention may be embodied in the form of a method for training a computer to identify a target biological material in a sample. The method may include accessing a plurality of training images, the training images being obtained by light microscopy of one or more samples containing a target biological material and optionally a non-target biological material. The training images are cropped by a human or a computer to produce cropped images, each of which shows predominantly the target biological material. A human then identifies the target biological material in each of the cropped images where identification is possible, and associating an identification label with each of the cropped images where identification was possible. A computer-implemented feature extraction method is then applied to each labelled cropped image. A computer-implemented learning method is then applied to each labelled cropped image to associate extracted features of a biological material with a target biological material.
PURPOSE:To obtain the subject new compound useful as a therapeutic agent for breast cancer, endometriosis, caner of uterine body, ovarian cancer, etc., having inhibitory action on aromatase by culturing a bacterium belonging to the genus Streptomyces, capable of producing SNA-60-367, etc. CONSTITUTION:A new compound, SNA-60-367 is expressed by the formula [X1 is an amino acid such as alanine, valine, aminobutyric acid or aminoisobutyric acid; X2 is an amino aid such as isoleucine or valine, etc.; R is an alkyl of the formula CnH2n+1 ((n) is 10-20 integer) or an alkoxyl of the formula CnH2n+1O], has inhibitory actin on aromatase, and is useful as a therapeutic agent for hormone-dependent diseases such as breast cancer, endometriosis, cancer of uterine body, ovarian cancer, etc. This compound is obtained by culturing a bacterium [e.g. Streptomyces sp. SNA-60-367 strain (FERM P-13, 704)] belonging to the genus Streptomyces, capable of producing SNA-60-367, extracting the supernatant liquid of th culture mixture and the cell with an organic solvent and collecting the product from the extracted solution.
GSK3732394 130 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 3 will be based on PK/PD results from preceding dosing cohorts.
Background: there is a decrease in adherence to the Mediterranean diet (MD) and an increase in the prevalence of excess weight among the Spanish child and adolescent population. Objectives: the objective of the present study was to determine the degree of adherence to MD and the nutritional status of the school population of Mataró (Spain) in order to obtain useful information for the design and application of future interventions. Material and methods: a cross-sectional descriptive study was carried out in a sample of 1177 schoolchildren between 6 and 18 years of age. The KIDMED index was used to assess adherence to MD, and the body mass index (BMI) to assess nutritional status. Questions were related to the students' perception of access to unhealthy foods, availability of money and parental interest in receiving nutrition education. Results: the percentage of children and adolescents with optimal adherence to MD does not reach 50 %, with secondary school youths presenting a lower percentage (30 %). Regarding the nutritional status of the sample, more than 70 % had a normal nutritional status according to their BMI, and 20.7 % of primary school students and 13.8 % of secondary school students were classified as overweight. Conclusions: the data confirm the interest of designing and implementing educational actions involving both students and parents, with the aim of improving the eating habits of the population. The results suggest that availability of money may facilitate access to unhealthy foods and, therefore, the promotion of healthy environments that increase the supply of healthy foods should be considered.
Safety and effectiveness in the pediatric population have not been established (see and ). Two placebo-controlled trials in 258 pediatric patients with MDD have been conducted with mirtazapine tablets, and the data were not sufficient to support a claim for use in pediatric patients. Anyone considering the use of mirtazapine tablets in a child or adolescent must balance the potential risks with the clinical need. BOXED WARNINGWARNINGS:Clinical Worsening and Suicide Risk

In an 8-week-long pediatric clinical trial of doses between 15 to 45 mg/day, 49% of mirtazapine-treated patients had a weight gain of at least 7%, compared to 5.7% of placebo-treated patients. The mean increase in weight was 4 kg (2 kg SD) for mirtazapine-treated patients versus 1 kg (2 kg SD) for placebo-treated patients (see ). PRECAUTIONS: Increased Appetite/Weight Gain
BACKGROUND: The immune microenvironment assumes a significant role in the pathogenesis of osteoarthritis (OA). However, the current biomarkers for the diagnosis and treatment of OA are not satisfactory. Our study aims to identify new OA immune-related biomarkers to direct the prevention and treatment of OA using multi-omics data.
METHODS: The discovery dataset integrated the GSE89408 and GSE143514 datasets to identify biomarkers that were significantly associated with the OA immune microenvironment through multiple machine learning methods and weighted gene co-expression network analysis (WGCNA). The identified signature genes were confirmed using two independent validation datasets. We also performed a two-sample mendelian randomization (MR) study to generate causal relationships between biomarkers and OA using OA genome-wide association study (GWAS) summary data (cases n = 24,955, controls n = 378,169). Inverse-variance weighting (IVW) method was used as the main method of causal estimates. Sensitivity analyses were performed to assess the robustness and reliability of the IVW results.
RESULTS: Three signature genes (FCER1G, HLA-DMB, and HHLA-DPA1) associated with the OA immune microenvironment were identified as having good diagnostic performances, which can be used as biomarkers. MR results showed increased levels of FCER1G (OR = 1.118, 95% CI 1.031-1.212, P = 0.041), HLA-DMB (OR = 1.057, 95% CI 1.045 -1.069, P = 1.11E-21) and HLA-DPA1 (OR = 1.030, 95% CI 1.005-1.056, P = 0.017) were causally and positively associated with the risk of developing OA.
CONCLUSION: The present study identified the 3 potential immune-related biomarkers for OA, providing new perspectives for the prevention and treatment of OA. The MR study provides genetic support for the causal effects of the 3 biomarkers with OA and may provide new insights into the molecular mechanisms leading to the development of OA.
The invention belongs to the technical field of drug research and development, and particularly relates to ligustrazine, a composition and application thereof. The present invention provides a composition comprising: lipase inhibitors and ligustrazine and/or ligustrazine derivatives. The invention also provides an application of the composition, the ligustrazine and the ligustrazine derivatives in medicines and/or health products for preventing and/or treating the increase of body weight or body fat content. The invention also provides an application of the composition, the ligustrazine and the ligustrazine derivatives in medicines and/or health products for preventing and/or treating the increase of body weight or body fat content. In the invention, the action mechanism and the corresponding effect of ligustrazine in reducing fat are found, and meanwhile, ligustrazine and a lipase inhibitor have synergistic action, and adverse reaction of the lipase inhibitor is reduced. The ligustrazine, the composition and the application thereof provided by the invention have the advantages of ensuring good weight reduction and/or fat reduction effects, simultaneously taking into account less adverse reaction and reducing the use cost.
Manganese 0.1 mg/mL (Manganese Chloride Injection, USP) contains 0.1 mg manganese/mL and is administered intravenously only after dilution. The additive should be administered in a volume of fluid at least 100 mL. For the adult receiving TPN, the suggested additive dosage for manganese is 55 mcg/day (0.55 mL/day).

Periodic monitoring of manganese plasma levels is suggested as a guideline for subsequent administration. (See WARNINGS.)

Parenteral products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (See PRECAUTIONS.)
PCT No. PCT/US96/20167 Sec. 371 Date Jun. 29, 1998 Sec. 102(e) Date Jun. 29, 1998 PCT Filed Dec. 17, 1996 PCT Pub. No. WO97/24105 PCT Pub. Date Jul. 10, 1997Hair coloring compositions comprise a preformed organic peroxyacid oxidizing agent selected from the group consisting of (i) a compound of the formula wherein X is a substituted or unsubstituted C12 alkyl group, and (ii) a compound of the formula wherein R1 is selected from the group consisting of alkyl, aryl and alkaryl groups with from 1 to 14 carbon atoms, R2 is selected from the group consisting of alkylene, arylene and alkarylene groups containing from 1 to 14 carbon atoms, and R5 is selected from the group consisting of H, alkyl, aryl and alkaryl groups containing 1 to 10 carbon atoms; and at least one oxidative hair coloring agent. The compositions are suitable for coloring human or animal hair and may be provided in a hair coloring kit comprising a single package including two separate bottles.